mni-968
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 3, 2017 (NCT03082768)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine D1 receptorAGONIST
DRD1 agonist
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- mni-968
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03142724 | Phase 1 | May 1, 2017 | Molecular NeuroImaging |
| NCT03082768 | Early Phase 1 (Phase 1) | Mar 3, 2017 | Molecular NeuroImaging |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Molecular NeuroImaging | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1